Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zynerba Pharmaceuticals Inc.

www.zynerba.com

Latest From Zynerba Pharmaceuticals Inc.

Critical Clinical Trial Updates Expected in 3Q

Ten clinical trial data readouts to watch for in the third quarter of 2017 that are expected to shift stocks and potentially change standard of care options in some disease areas.

Clinical Trials Research and Development Strategies

Deals Shaping The Medical Industry, February 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017

Deals BioPharmaceutical

Pipeline Watch: Phase III Starts In MS, Hyperkalemia And Short Stature

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Research & Development Pipeline Watch

Pipeline Watch: Phase III Results For New Antibiotics And Long-Acting HIV/AIDS Biologic

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • AllTranz Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Zynerba Pharmaceuticals Inc.
  • Senior Management
  • Armando Anido, Chmn. & CEO
    Jim Fickenscher, CFO & VP, Corp. Dev.
    Carol O'Neill, VP, Dev.
    Terri B Sebree, President
    Nancy Tich, PhD, VP, Clinical
    Donna Gutterman, PharmD, VP, Medical
  • Contact Info
  • Zynerba Pharmaceuticals Inc.
    Phone: (484) 581-7505
    80 W. Lancaster Ave.
    Ste. 300
    Devon, PA 19333
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register